Addressing the treatment gap for patients with relapsed/refractory primary systemic AL amyloidosis: TOURMALINE-AL1 trial results

Bookmark and Share
This video is restricted to members who are registered with ecancer as a healthcare professional
Please login or register for free to confirm your details.
Published: 9 Dec 2019
Views: 1257
Prof Evangelos Terpos and Prof Efstathios Kastritis

Prof Evangelos Terpos (University of Athens, Athens, Greece) and Prof Efstathios Kastritis (University of Athens, Athens, Greece) discuss the treatment landscape for patients with relapsed/refractory primary systemic AL amyloidosis (RRAL).

Prof Kastritis gives an overview of this rare disease type including the challenges associated with the diagnosis, treatment and prognosis of these patients. He explains that these patients typically experience co-morbidities including cardiac dysfunction, which makes treatment especially challenging.

The experts discuss the results from the TOURMALINE-AL1 trial which investigated the use of ixazomib-dexamethasone patients with RRAL and favours the use of this combination compared to the physician’s choice.

Prof Kastritis concludes by stating that this is the best treatment option in relapsed/refractory setting – in which no standard of care has been established thus far.

This programme has been supported by an unrestricted educational grant from Takeda.

What is systemic AL amyloidosis and how is it diagnosed?
Staging of systemic AL amyloidosis
Treatment for newly-diagnosed patients
Results from the TOURMALINE-AL1 trial
Use of ixazomib-dexamethasone in the relapsed/refractory setting